Visit DOTmed at RSNA, North Hall B, Booth #6608 -- Ask about Clean Sweep Equipment Auctions

Current Location:
> This Story

Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

Never Miss a Story

Sign up for email alerts


More Industry Headlines

New scattered X-ray method delivers a whole new view of your tooth Measuring structures as small as a billionth of a meter

Breast MR after mammography may catch additional aggressive cancers How clinically significant are multicentric cancers?

Bilingual patients have better cognitive function after stroke But it may not apply to all bilingual people

Will the future hold compact, tunable X-ray devices made of graphene? May reduce radiation dose and cost associated with current X-ray devices

Dell announces entry into health care monitor market New device is designed to meet IEC 60601-1 standard

Canadian hospital clerk who sold maternity records fined $27,000 — hospital facing $308.4 million suit From 1995 to 2014 she sold at least 14,450 records

Google Glass used to treat blocked coronary artery for first time A more economical option

UnitedHealth scaling back efforts in ACA exchanges May quit them entirely in 2017

Discover Cinematic Rendering technology A talk with Dr. Dorin Comaniciu, vice president of Siemens’ Medical Imaging Technologies

Bundled payments to overhaul lucrative total joint replacement surgery sector The new rule will be initially rolled out in 67 metropolitan areas in April of 2016

(Courtesy FDA)

Radiopharmaceutical cleared for breast and skin cancer

by Loren Bonner , DOTmed News Online Editor
On Wednesday, the U.S. Food and Drug Administration approved a new radioactive diagnostic imaging agent used to help doctors with the staging and management of breast and melanoma cancer patients.

According to Frederic H. Fahey, DSc, president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the new drug, technetium Tc 99m tilmanocept (Lymphoseek), will give doctors a more accurate way to find the sentinel lymph node, which in turn will help them determine where the patient's cancer has spread.

Story Continues Below Advertisement

One Coil. Multiple applications

Improve current examinations and reduce scan times by replacing old technology with state of the art 16 channel high density technology. Increase revenue with added capabilities from pediatrics to geriatrics. THIS IS YOUR ONE COIL

During the standard sentinel node biopsy procedure for breast and melanoma cancer patients, which determines if the cancer has spread beyond the primary tumor and into the lymphatic system, doctors use a handheld radioactive detector to find which lymph nodes have been taken up by the agent's radioactivity. They remove them and look for cancer.

"Tc 99m tilmanocept lets you be more confident that you are taking the correct lymph node out," Fahey told DOTmed News.

Previous lymph node mapping agents — including sulfur colloid and isosulfan blue — were based on the size of the particle and would occasionally miss the correct sentinel lymph nodes. Sulfur colloid was approved by the FDA in 1974 and isosulfan blue in 1981.

Over 30 years later, the arrival of a new lymph node mapping agent — Lymphoseek — is a testament to the advancements in molecular imaging that have taken place over the past 10 to 15 years.

"It's a receptor-based agent that targets receptors on the surface of the lymphatic cells," said Fahey. "It has more of targeted approach to how it decides what the sentinel lymph node is."

In other words, whether the agent goes to the correct lymph node is no longer based on the size of the particle; instead it depends on the agent actually seeking out the lymphatic cells and sticking to them, according to Fahey.

For patients, this means the agent can be injected in a more convenient manner because it stays in place for a longer period of time.

"You can inject the agent on the day of the surgery or inject it the day before surgery," said Fahey.

According to a statement from the FDA, data from the clinical trials that established approval of the drug showed a notable number of nodes were localized only by Lymphoseek, compared with blue dye, another drug used to help locate lymph nodes.

The trials consisted of 332 patients in two trials with melanoma or breast cancer. All patients were injected with Lymphoseek and blue dye.

Lymphoseek is marketed by the Dublin, Ohio-based Navidea Biopharmaceuticals Inc., but will be distributed in the U.S. by Cardinal Health Inc., according to a statement from Navidea Biopharmaceuticals.

Back to DOTmed News
  Pages: 1


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

You Must Be Logged In To Post A Comment

Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Gold Service Dealer Program
Receive RFP/PS
Healthcare Providers
See all
HCP Tools
A Job
Parts Hunter +EasyPay
Get Parts
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2015 DOTmed.com, Inc.